Saturday 17 October 2026
Export SCNX’s income statement to Excel — free account
Scienture Holdings, Inc.
SCNX Healthcare Pharmaceutical Retailers
Scienture Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $431,600.00, up 216.0% from fiscal 2024. In the quarter to June 2026, revenue grew 3,235.9%, EPS grew 85.4%, free cash flow fell 54.0% and total debt rose 831.4%, each against the same quarter a year earlier.
3.31
0.07
−2.07%
Follow SCNX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
422.06 | 593.65 | 403.62 | 560.77 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(110.67) | (99.24) | (37.81) | (125.36) | |
P/B ratio |
5.41 | 4.34 | 2.79 | 4.87 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
424.39 | 590.71 | 394.23 | 563.21 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(24.14) | (21.60) | (14.28) | (36.41) | |
EV/FCF |
(20.50) | (18.12) | (11.99) | (29.58) | |
Quick Ratio |
2.83 | 1.52 | 2.70 | 0.13 | |
Current Ratio |
3.04 | 1.70 | 2.89 | 0.19 | |
Net Debt/EBITDA |
(0.64) | 1.16 | 0.23 | (0.07) | |
Debt/Assets |
10.91% | 0.00% | 0.00% | 0.51% | |
Debt/Equity |
0.15 | 0.00 | 0.00 | 0.01 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
1.11 | 0.86 | 0.18 | 0.89 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(10.01) | (94.85) | (30.87) | (2.42) | |
Research and Development Expense of Revenue |
339.52% | 1,410.30% | (218.55%) | 28.69% | |
Selling, General and Administrative Expense of Revenue |
227.07% | 2,655.24% | (1,110.79%) | 409.61% | |
Intangible Assets out of Total Assets |
0.80 | 0.87 | 0.84 | 0.93 | |
Share Based Compensation of Revenue |
30.12% | 181.71% | (198.64%) | 355.84% | |
Graham Net Nets |
(0.04) | (0.03) | (0.03) | (0.05) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(24.00%) | (35.20%) | (21.65%) | (76.03%) | |
Free Cash Flow Yield |
(4.91%) | (5.49%) | (8.15%) | (3.40%) | |
Revenue per Share |
0.01 | 0.00 | (0.01) | 0.03 | |
Operating CF per Share |
(0.08) | (0.07) | (0.34) | (0.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.08) | (0.07) | (0.34) | (0.17) | |
Cash per Share |
0.21 | 0.09 | 0.43 | 0.02 | |
Shareholders Equity per Share |
1.62 | 1.64 | 4.57 | 4.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.62 | 1.64 | 4.57 | 4.36 | |
Free Cash Flow |
(3.13) | (2.92) | (5.18) | (3.21) | |
Working Capital |
6.18 | 1.97 | 5.18 | (5.93) | |
Net Current Asset Value |
(14.43) | (9.07) | (6.14) | (20.74) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.22 | 2.44 | 2.62 | 1.42 | |
Average Payables |
2.03 | 2.29 | 2.17 | 3.29 | |
Average Inventory |
0.11 | 0.11 | 0.11 | 0.12 | |
Average Assets |
96.01 | 93.51 | 94.52 | 99.55 | |
Average Common Equity |
70.98 | 73.99 | 74.60 | 83.90 |
Columns are period end dates